Setterwalls has advised Sound Bioventures, Novo Holdings och Pueros Bioventures in connection with investment in AnaCardio

Setterwalls has advised Sound Bioventures, Novo Holdings and Pureos Bioventures in connection with a USD 19 million Series A extension financing round in AnaCardio.

The current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated in the financing round.

AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. The raised funds will be used to complete the phase 1b/2a GOAL-HF1 study, and to prepare and initiate start-up activities for the subsequent phase 2b study.